# About Thymosin Alpha-1 Research: An Independent Editorial Digest

> Thymosin Alpha-1 Research is an independent editorial project summarizing the peer-reviewed literature on Thymosin Alpha-1. Not a clinic, not a vendor, no medical advice.

An independent editorial digest of the published Thymosin Alpha-1 literature — what the studies measured, graded by how strong the evidence is.

## What this site is

Thymosin Alpha-1 Research is an independent editorial project that publishes summaries of the peer-reviewed research literature on Thymosin Alpha-1 (thymalfasin), the 28-amino-acid thymic immunomodulatory peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "research" in our name describes the position we occupy relative to the literature — a reading desk that summarizes and grades published studies — not a claim that we conduct trials, offer treatment, or supply the compound. There is no clinic, pharmacy, or storefront behind this site.

## How we read the evidence

We treat the Thymosin Alpha-1 record as a titration of evidence strength: some settings carry strong, reproducible human data (chronic viral hepatitis), some are null in the best trials (sepsis), some are mixed (COVID-19), and some are exploratory (HIV immune reconstitution). We report findings as study-attributed — tied to the population, dose, and route actually used — and we never assert unproven human benefit as established fact. Where a setting carries conflicting evidence, we cite the conflicting studies together.

We are careful about identity. Thymosin Alpha-1 is constantly confused with other thymic peptides, and we keep it distinct throughout from thymosin beta-4 / TB-500, thymulin, thymopentin, thymalin, and its own precursor prothymosin alpha. We also state regulatory reality plainly: it is not FDA-approved for marketing in the United States.

## What we do not do

We do not give dosing for personal use, recommend the compound, or imply it is safe or effective for any individual. We do not name any commercial brand of the peptide. We do not host a person, address, phone number, or clinical team — there are none to host. We summarize what the literature found, cite it, and leave clinical decisions where they belong: with qualified clinicians and the primary evidence on the [references](/references) page.

---

A titration reading of the Thymosin Alpha-1 (thymalfasin) record — the thymic immunomodulator's strongest hepatitis-B signal logged first, the null phase-3 sepsis trial and the US non-approval held in plain sight, and the molecule kept ruled apart from thymosin beta-4, thymulin, and thymopentin; no clinic behind the rail and nothing here dosed, dispensed, or sold.